Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Deodhar

Showing results (41-50 of 92) with videos related to

Pageof 10
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Long-Term Maintenance of Improvements in Patient-Reported Outcomes With Certolizumab Pegol in Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 96-Week Results of the Rapid-Axspa StudyJ Sieper, A Kivitz, A van Tubergen, et al.
Arthritis Care & Research|April 3, 2015
Impact of Certolizumab Pegol on Patient-Reported Outcomes in Patients With Axial SpondyloarthritisJ Sieper, A Kivitz, A van Tubergen, et al.
Annals of the Rheumatic Diseases|January 25, 2018
Elephant in the roomDaniel M Hartung, Kirbee Johnston, David M Cohen, et al.
Arthritis Care & Research|October 4, 2016
Early Disease Activity or Clinical Response as Predictors of Long-Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic ArthritisD van der Heijde, A Deodhar, R Fleischmann, et al.
JAMA Internal Medicine|December 13, 2021
Characterization of the Clinical Evidence Supporting Repository Corticotropin Injection for FDA-Approved Indications: A Scoping ReviewKim A Tran, Curtis Harrod, Dennis N Bourdette, et al.
Annals of the Rheumatic Diseases|May 23, 2008
Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitisS Visvanathan, D van der Heijde, A Deodhar, et al.
The Journal of Rheumatology|April 5, 2007
A combination of 6 months of treatment with pyridostigmine and triweekly exercise fails to improve insulin-like growth factor-I levels in fibromyalgia, despite improvement in the acute growth hormone response to exerciseKim Dupree Jones, Atul A Deodhar, Carol S Burckhardt, et al.
Clinical Rheumatology|May 6, 2020
Propensity score matching/reweighting analysis comparing intravenous golimumab to infliximab for ankylosing spondylitis using data from the GO-ALIVE and ASSERT trialsL S Gensler, S D Chakravarty, Chris Cameron, et al.
Arthritis and Rheumatism|February 2, 2008
A six-month randomized controlled trial of exercise and pyridostigmine in the treatment of fibromyalgiaK D Jones, C S Burckhardt, A A Deodhar, et al.
Clinical Rheumatology|May 16, 2014
A novel, short, and simple screening questionnaire can suggest presence of psoriatic arthritis in psoriasis patients in a dermatology clinicN Garg, B Truong, J H Ku, et al.
Pageof 10

Showing results (41-50 of 92) with videos related to

Sort By:
Pageof 10
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Long-Term Maintenance of Improvements in Patient-Reported Outcomes With Certolizumab Pegol in Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 96-Week Results of the Rapid-Axspa StudyJ Sieper, A Kivitz, A van Tubergen, et al.
Arthritis Care & Research|April 3, 2015
Impact of Certolizumab Pegol on Patient-Reported Outcomes in Patients With Axial SpondyloarthritisJ Sieper, A Kivitz, A van Tubergen, et al.
Annals of the Rheumatic Diseases|January 25, 2018
Elephant in the roomDaniel M Hartung, Kirbee Johnston, David M Cohen, et al.
Arthritis Care & Research|October 4, 2016
Early Disease Activity or Clinical Response as Predictors of Long-Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic ArthritisD van der Heijde, A Deodhar, R Fleischmann, et al.
JAMA Internal Medicine|December 13, 2021
Characterization of the Clinical Evidence Supporting Repository Corticotropin Injection for FDA-Approved Indications: A Scoping ReviewKim A Tran, Curtis Harrod, Dennis N Bourdette, et al.
Annals of the Rheumatic Diseases|May 23, 2008
Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitisS Visvanathan, D van der Heijde, A Deodhar, et al.
The Journal of Rheumatology|April 5, 2007
A combination of 6 months of treatment with pyridostigmine and triweekly exercise fails to improve insulin-like growth factor-I levels in fibromyalgia, despite improvement in the acute growth hormone response to exerciseKim Dupree Jones, Atul A Deodhar, Carol S Burckhardt, et al.
Clinical Rheumatology|May 6, 2020
Propensity score matching/reweighting analysis comparing intravenous golimumab to infliximab for ankylosing spondylitis using data from the GO-ALIVE and ASSERT trialsL S Gensler, S D Chakravarty, Chris Cameron, et al.
Arthritis and Rheumatism|February 2, 2008
A six-month randomized controlled trial of exercise and pyridostigmine in the treatment of fibromyalgiaK D Jones, C S Burckhardt, A A Deodhar, et al.
Clinical Rheumatology|May 16, 2014
A novel, short, and simple screening questionnaire can suggest presence of psoriatic arthritis in psoriasis patients in a dermatology clinicN Garg, B Truong, J H Ku, et al.
Pageof 10